MedTrace Logo

Aspirin and Plavix Following Coronary Artery Bypass Grafting

NCT01158703 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-05-19

Study results available
· View outcomes & findings →

Summary

The design of the study will be randomized, double blind trial, which will examine the effects of addition of clopidogrel to current guideline recommended background therapy on lowering the incidence of graft stenosis after coronary artery bypass grafting compared to placebo.

Conditions

  • Coronary Graft Patency

Interventions

DRUG

clopidogrel

clopidogrel 75mg daily by mouth daily for 12 months

DRUG

sugar pill

sugar pill by mouth daily for 12 months

DRUG

Aspirin

aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)

Sponsors & Collaborators

Principal Investigators

  • Ahmad M Slim, MD · Brooke Army Medical Center

  • Rachel Beck, MD · Brooke Army Medical Center

  • William Conner, MD · Brooke Army Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01158703 on ClinicalTrials.gov